Corcept Therapeutics Incorporated
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | +63.9% | -56.6% | -86.1% | – | – | – | +213.2% | +156.4% | +89.4% | +61.7% | +95.8% | +57.8% | +22.0% | +15.5% | +3.4% | +9.8% | +20.0% | +39.9% | +12.8% | |
| – | – | – | – | – | – | – | -50.8% | +56.4% | +1.9% | – | – | – | +57.1% | +516.8% | +54.3% | +51.2% | +72.7% | +46.7% | +5.5% | +1.4% | -5.4% | +2.0% | +20.4% | +67.9% | +19.3% | |
| – | – | – | – | – | – | – | +63.9% | -56.6% | -86.1% | – | – | – | +217.6% | +151.3% | +90.6% | +62.0% | +96.4% | +58.1% | +22.3% | +15.7% | +3.6% | +9.9% | +20.0% | +39.6% | +12.7% | |
| – | +308.6% | +146.1% | -38.9% | +42.5% | +47.8% | +22.0% | -62.3% | +80.1% | +1.8% | +31.6% | +10.8% | -33.0% | +45.4% | -10.2% | -16.1% | +54.6% | +69.3% | +86.4% | +18.3% | +28.9% | -0.8% | +15.0% | +40.7% | +33.9% | +3.2% | |
| – | – | – | -46.9% | +44,971.3% | -99.9% | +23.5% | -3.5% | +18.1% | +2.3% | +44.4% | +33.5% | +124.3% | +22.9% | +11.8% | +5.8% | +22.4% | +38.0% | +30.2% | +23.5% | +4.9% | +16.2% | +24.9% | +20.6% | +52.1% | +60.1% | |
| – | – | +134.8% | -46.8% | +60.5% | +31.9% | +22.3% | -50.8% | +56.3% | +1.9% | +35.3% | +17.8% | +22.1% | +31.0% | +3.1% | -1.7% | +31.9% | +48.8% | +52.3% | +21.0% | +16.2% | +7.3% | +20.2% | +29.9% | +43.0% | +33.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +419.3% | +69.3% | +24.7% | +14.9% | -2.9% | -9.5% | -4.8% | +27.7% | -67.3% | |
| – | – | – | – | – | – | – | – | – | -89.3% | +1,381.2% | -99.8% | +59,100.0% | +154.2% | -16.6% | -21.2% | -31.2% | -97.6% | +5,322.4% | +90.8% | +11.2% | -36.2% | -1.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +548.7% | +74.5% | +26.6% | +12.8% | -5.0% | -7.1% | +7.2% | +29.7% | -58.8% | |
| – | – | +148.2% | -101.0% | – | – | – | – | – | -122.6% | – | – | -100.0% | – | – | – | – | – | – | +34.4% | +13.8% | -51.2% | +18.2% | +24.7% | +10.1% | -263.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +1,486.3% | -41.6% | +24.9% | +12.6% | +6.1% | -9.9% | +4.7% | +31.6% | -28.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +415.9% | +69.4% | +26.8% | +14.6% | -2.2% | -9.4% | +8.6% | +29.6% | -58.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.